
Edwards Lifesciences Corporation EW
$ 88.07
0.61%
Quarterly report 2026-Q1
added 05-06-2026
Edwards Lifesciences Corporation Accounts Receivables 2011-2026 | EW
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Edwards Lifesciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 660 M | 609 M | 772 M | 643 M | 582 M | 515 M | 544 M | 457 M | 422 M | 366 M | 315 M | 288 M | 302 M | 321 M | 284 M | 277 M | 249 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 772 M | 249 M | 447 M |
Quarterly Accounts Receivables Edwards Lifesciences Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 776 M | 693 M | 697 M | 669 M | 609 M | 716 M | 778 M | 818 M | 772 M | 740 M | 754 M | 718 M | 643 M | 618 M | - | 636 M | 582 M | 601 M | 640 M | 587 M | 515 M | 515 M | 515 M | 515 M | 544 M | 544 M | 610 M | 599 M | 457 M | 424 M | 431 M | 407 M | 439 M | 439 M | 439 M | 422 M | 366 M | 454 M | 415 M | 415 M | 315 M | 338 M | 344 M | 344 M | 288 M | 323 M | 325 M | 325 M | 302 M | 328 M | 328 M | 328 M | 321 M | 325 M | 336 M | 347 M | 321 M | 347 M | 321 M | 321 M | 303 M | 294 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 818 M | 288 M | 486 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
EDAP TMS S.A.
EDAP
|
18.6 M | $ 4.39 | 1.74 % | $ 164 M | ||
|
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
57.2 M | - | - | $ 3.31 B | ||
|
Eargo
EAR
|
1.91 M | - | - | $ 10.2 M | ||
|
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | ||
|
ClearPoint Neuro
CLPT
|
6.55 M | $ 11.67 | -1.27 % | $ 330 M | ||
|
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
97.3 M | $ 8.02 | -0.56 % | $ 1.2 B | ||
|
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | ||
|
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | ||
|
LENSAR
LNSR
|
6.38 M | $ 6.0 | -0.83 % | $ 71.7 M | ||
|
Helius Medical Technologies
HSDT
|
70 K | $ 2.23 | -3.04 % | $ 49.2 M | ||
|
IRIDEX Corporation
IRIX
|
7.61 M | $ 1.04 | -0.01 % | $ 17.6 M | ||
|
Pulmonx Corporation
LUNG
|
12.1 M | $ 1.59 | 0.96 % | $ 64.7 M | ||
|
Cytosorbents Corporation
CTSO
|
7.55 M | $ 0.45 | -3.29 % | $ 28 M | ||
|
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 18.06 | 0.89 % | $ 424 M | ||
|
Delcath Systems
DCTH
|
11.7 M | $ 11.25 | 3.88 % | $ 403 M | ||
|
Myomo
MYO
|
4.1 M | $ 1.03 | - | $ 43.1 M | ||
|
LivaNova PLC
LIVN
|
216 M | $ 75.5 | 0.1 % | $ 4.12 B | ||
|
Orthofix Medical
OFIX
|
136 M | $ 9.51 | -2.66 % | $ 377 M | ||
|
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | ||
|
MiMedx Group
MDXG
|
75.7 M | $ 3.68 | 0.27 % | $ 544 M | ||
|
Profound Medical Corp.
PROF
|
7.2 M | $ 6.9 | 1.92 % | $ 209 M | ||
|
Electromed
ELMD
|
24.7 M | $ 38.4 | 0.26 % | $ 325 M | ||
|
Butterfly Network
BFLY
|
26.7 M | $ 4.67 | 2.75 % | $ 1.15 B | ||
|
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | ||
|
Sintx Technologies
SINT
|
178 K | $ 2.34 | -3.91 % | $ 6.49 M | ||
|
GBS
GBS
|
595 K | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
679 M | $ 84.67 | -0.51 % | $ 11.4 B | ||
|
Insulet Corporation
PODD
|
141 M | $ 143.99 | -6.38 % | $ 10.1 B | ||
|
CONMED Corporation
CNMD
|
248 M | $ 36.81 | 2.08 % | $ 1.14 B | ||
|
Inspire Medical Systems
INSP
|
120 M | $ 43.03 | 2.48 % | $ 1.26 B | ||
|
Integer Holdings Corporation
ITGR
|
346 M | $ 90.15 | 0.01 % | $ 3.13 B | ||
|
Invacare Corporation
IVC
|
88 M | - | - | $ 24.7 M | ||
|
TransMedics Group
TMDX
|
84.3 M | $ 69.38 | -1.53 % | $ 2.36 B |